Table 2.
Relationship between EML4‐ALK gene fusion and clinicopathological profiles in younger (≤ 50 years) patients with lung adenocarcinoma
| Total | EML4‐ALK | ||||||
|---|---|---|---|---|---|---|---|
| (n = 49) | Positive (n = 5) | Negative (n = 44) | P | ||||
| Variable | No. | (%) | No. | (%) | No. | (%) | |
| Age, years | |||||||
| Median | 48 | 47 | 48 | 0.560 | |||
| Range | 31–50 | 37–50 | 31–50 | ||||
| Gender | |||||||
| Male | 23 | (47) | 2 | (40) | 21 | (48) | 0.743 |
| Female | 26 | (53) | 3 | (60) | 23 | (52) | |
| Smoking history | |||||||
| Non‐smoker | 27 | (55) | 3 | (60) | 24 | (55) | 0.816 |
| Ever smoker | 22 | (45) | 2 | (40) | 20 | (45) | |
| Pathology | |||||||
| With lepidic growth | 16 | (33) | 0 | (0) | 16 | (36) | 0.100 |
| Without lepidic growth | 33 | (67) | 5 | (100) | 27 | (64) | |
| Stage | |||||||
| I | 23 | (47) | 1 | (20) | 22 | (50) | 0.002 |
| II | 4 | (8) | 0 | (0) | 4 | (9) | |
| III | 15 | (31) | 1 | (20) | 14 | (32) | |
| IV | 7 | (14) | 3 | (60) | 4 | (9) | |
| EGFR | |||||||
| Wild type | 36 | (73) | 5 | (100) | 31 | (70) | 0.156 |
| Mutation | 13 | [27] | 0 | [0] | 13 | [30] | |
| KRAS | |||||||
| Wild type | 48 | [98] | 5 | [100] | 43 | [98] | 0.733 |
| Mutation | 1 | [2] | 0 | [0] | 1 | [2] | |
Stages I–III versus IV.